Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Moderna, Inc.MRNA · Entity 2025 | General Counsel and Secretary | May 27, 2021 | May 28, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Moderna, Inc.
Report date May 27, 2021 · Filed May 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 901 |
Ending reported balance
After 2021-05-27 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-05-27 · Exercise / conversion · Acquired 6,600 · Balance 7,501 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Row 2 · 2021-05-27 · Sale · Disposed 6,600 · Balance 901 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.85 · Expires 2028-06-26 | Direct | 328,352 |
Reported balance
After 2021-05-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-05-27 · Exercise / conversion · Disposed 6,600 · Balance 328,352 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. F2: 25% of this option will vest and become exercisable on April 9, 2019 with the remainder vesting in 12 equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020.
F2: 25% of this option will vest and become exercisable on April 9, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALBANY MOLECULAR RESEARCH INC
Report date August 31, 2017 · Filed September 05, 2017
Section 16 reporting ended · disclosed 2017-09-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,138 |
Reported balance
After 2017-08-28 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2017-08-28 · Gift · Disposed 9,857 · Balance 52,138 F1: This transaction involved a gift of securities by Ms. Lori Henderson. Ms. Henderson disclaims beneficial ownership of these shares and this report shall not be deemed an admission that Ms. Henderson is the beneficial owner of such securities for the purpose of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 66,717 |
Reported balance
After 2017-08-31 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2017-08-31 · Grant · Acquired 4,722 · Balance 66,717 |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2017-08-31 · Disposition to issuer · Disposed 66,717 · Balance 0 F2: Disposed of pursuant to the Agreement and Plan of Merger, dated as of June 5, 2017, by and among Albany Molecular Research, Inc. ("AMRI"), UIC Parent Corporation ("UIC Parent"), and UIC Merger Sub, Inc. ("UIC Sub") (the "Merger Agreement"). The Merger Agreement provides that each share of AMRI common stock and each outstanding restricted stock unit automatically be canceled and converted into the right to receive $21.75 in cash, without interest and less any applicable withholding taxes (the "Merger Consideration"). |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $4.87 · Expires 2021-02-04 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-08-31 · Disposition to issuer · Disposed 50,000 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $5.25 · Expires 2021-06-02 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-08-31 · Disposition to issuer · Disposed 17,500 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.93 · Expires 2022-02-17 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-08-31 · Disposition to issuer · Disposed 4,375 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.93 · Expires 2022-02-17 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-08-31 · Disposition to issuer · Disposed 4,375 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.93 · Expires 2022-02-17 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-08-31 · Disposition to issuer · Disposed 17,500 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $5.99 · Expires 2023-01-31 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2017-08-31 · Disposition to issuer · Disposed 4,375 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $5.99 · Expires 2023-01-31 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2017-08-31 · Disposition to issuer · Disposed 17,500 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $5.99 · Expires 2023-01-31 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2017-08-31 · Disposition to issuer · Disposed 4,375 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $5.99 · Expires 2023-01-31 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2017-08-31 · Disposition to issuer · Disposed 4,375 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $10.43 · Expires 2024-02-04 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2017-08-31 · Disposition to issuer · Disposed 29,167 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $17.05 · Expires 2025-03-02 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2017-08-31 · Disposition to issuer · Disposed 22,893 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $15.77 · Expires 2026-02-04 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2017-08-31 · Disposition to issuer · Disposed 29,066 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.41 · Expires 2027-02-08 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2017-08-31 · Disposition to issuer · Disposed 44,251 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction involved a gift of securities by Ms. Lori Henderson. Ms. Henderson disclaims beneficial ownership of these shares and this report shall not be deemed an admission that Ms. Henderson is the beneficial owner of such securities for the purpose of Section 16 or any other purpose.
F2: Disposed of pursuant to the Agreement and Plan of Merger, dated as of June 5, 2017, by and among Albany Molecular Research, Inc. ("AMRI"), UIC Parent Corporation ("UIC Parent"), and UIC Merger Sub, Inc. ("UIC Sub") (the "Merger Agreement"). The Merger Agreement provides that each share of AMRI common stock and each outstanding restricted stock unit automatically be canceled and converted into the right to receive $21.75 in cash, without interest and less any applicable withholding taxes (the "Merger Consideration").
F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2017 Filed Sep 5, 2017 16:26 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerOption to Purchase Common Stock · Derivative | 29,167 | $11.32 Strike: $10.43 | $330,170.44 |
DisclosureSEC source: 0001638599-17-000866 · doc4_4892.xml · derivative · entry 13 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,167 shares Expires 2024-02-04 F3 · derivative.exercise_date: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:26 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerOption to Purchase Common Stock · Derivative | 4,375 | $15.76 Strike: $5.99 | $68,950.00 |
DisclosureSEC source: 0001638599-17-000866 · doc4_4892.xml · derivative · entry 12 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,375 shares Expires 2023-01-31 F3 · derivative.exercise_date: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:26 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerOption to Purchase Common Stock · Derivative | 4,375 | $15.76 Strike: $5.99 | $68,950.00 |
DisclosureSEC source: 0001638599-17-000866 · doc4_4892.xml · derivative · entry 11 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,375 shares Expires 2023-01-31 F3 · derivative.exercise_date: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:26 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerOption to Purchase Common Stock · Derivative | 17,500 | $15.76 Strike: $5.99 | $275,800.00 |
DisclosureSEC source: 0001638599-17-000866 · doc4_4892.xml · derivative · entry 10 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires 2023-01-31 F3 · derivative.exercise_date: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:26 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerOption to Purchase Common Stock · Derivative | 4,375 | $15.76 Strike: $5.99 | $68,950.00 |
DisclosureSEC source: 0001638599-17-000866 · doc4_4892.xml · derivative · entry 9 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,375 shares Expires 2023-01-31 F3 · derivative.exercise_date: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:26 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerOption to Purchase Common Stock · Derivative | 17,500 | $18.82 Strike: $2.93 | $329,350.00 |
DisclosureSEC source: 0001638599-17-000866 · doc4_4892.xml · derivative · entry 8 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires 2022-02-17 F3 · derivative.exercise_date: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:26 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerOption to Purchase Common Stock · Derivative | 4,375 | $18.82 Strike: $2.93 | $82,337.50 |
DisclosureSEC source: 0001638599-17-000866 · doc4_4892.xml · derivative · entry 7 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,375 shares Expires 2022-02-17 F3 · derivative.exercise_date: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:26 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerOption to Purchase Common Stock · Derivative | 4,375 | $18.82 Strike: $2.93 | $82,337.50 |
DisclosureSEC source: 0001638599-17-000866 · doc4_4892.xml · derivative · entry 6 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,375 shares Expires 2022-02-17 F3 · derivative.exercise_date: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:26 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerOption to Purchase Common Stock · Derivative | 17,500 | $16.50 Strike: $5.25 | $288,750.00 |
DisclosureSEC source: 0001638599-17-000866 · doc4_4892.xml · derivative · entry 5 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires 2021-06-02 F3 · derivative.exercise_date: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:26 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerOption to Purchase Common Stock · Derivative | 50,000 | $16.88 Strike: $4.87 | $844,000.00 |
DisclosureSEC source: 0001638599-17-000866 · doc4_4892.xml · derivative · entry 4 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2021-02-04 F3 · derivative.exercise_date: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:26 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerCommon Stock | 66,717 | $21.75 | $1,451,094.75 |
DisclosureSEC source: 0001638599-17-000866 · doc4_4892.xml · nonDerivative · entry 3 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated as of June 5, 2017, by and among Albany Molecular Research, Inc. ("AMRI"), UIC Parent Corporation ("UIC Parent"), and UIC Merger Sub, Inc. ("UIC Sub") (the "Merger Agreement"). The Merger Agreement provides that each share of AMRI common stock and each outstanding restricted stock unit automatically be canceled and converted into the right to receive $21.75 in cash, without interest and less any applicable withholding taxes (the "Merger Consideration"). Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:26 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | GrantCommon Stock | 4,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000866 · doc4_4892.xml · nonDerivative · entry 2 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,717 Read SEC document |
| August 28, 2017 Filed Sep 5, 2017 16:26 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | GiftCommon Stock | 9,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000866 · doc4_4892.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,138 F1 · shares: This transaction involved a gift of securities by Ms. Lori Henderson. Ms. Henderson disclaims beneficial ownership of these shares and this report shall not be deemed an admission that Ms. Henderson is the beneficial owner of such securities for the purpose of Section 16 or any other purpose. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 16:08 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Tax withholdingCommon Stock | 432 | $14.52 | $6,272.64 |
DisclosureSEC source: 0001144204-17-012947 · v461189_4.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,995 F1 · kind: Consists of shares withheld by Albany Molecular Research, Inc. in order to satisfy the minimum tax withholding obligation of the reporting person. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 16:05 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | GrantOption to Purchase Common Stock · Derivative | 44,251 | $0.00 Strike: $18.41 | $0.00 |
DisclosureSEC source: 0001638599-17-000191 · doc4_4536.xml · derivative · entry 3 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,251 Underlying: Common Stock · 44,251 shares Expires 2027-02-08 F1 · derivative.exercise_date: Option is exercisable as to 1/4th of the shares annually on the anniversary date of the grant for each of the next four years. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 16:05 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | GrantCommon Stock | 6,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000191 · doc4_4536.xml · nonDerivative · entry 2 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,427 Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 16:05 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | GrantCommon Stock | 8,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000191 · doc4_4536.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,680 Read SEC document |
| February 04, 2017 Filed Feb 7, 2017 16:39 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Tax withholdingCommon Stock | 504 | $18.52 | $9,334.08 |
DisclosureSEC source: 0001638599-17-000161 · doc4_4528.xml · nonDerivative · entry 3 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,690 F1 · kind: Consists of shares withheld by Albany Molecular Research, Inc. in order to satisfy the minimum tax withholding obligation of the reporting person. Read SEC document |
| February 04, 2017 Filed Feb 7, 2017 16:39 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Tax withholdingCommon Stock | 674 | $18.52 | $12,482.48 |
DisclosureSEC source: 0001638599-17-000161 · doc4_4528.xml · nonDerivative · entry 2 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,194 F1 · kind: Consists of shares withheld by Albany Molecular Research, Inc. in order to satisfy the minimum tax withholding obligation of the reporting person. Read SEC document |
| February 04, 2017 Filed Feb 7, 2017 16:39 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Tax withholdingCommon Stock | 2,363 | $18.52 | $43,762.76 |
DisclosureSEC source: 0001638599-17-000161 · doc4_4528.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,868 F1 · kind: Consists of shares withheld by Albany Molecular Research, Inc. in order to satisfy the minimum tax withholding obligation of the reporting person. Read SEC document |
| January 31, 2017 Filed Feb 1, 2017 16:07 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Tax withholdingCommon Stock | 553 | $18.11 | $10,014.83 |
DisclosureSEC source: 0001638599-17-000135 · doc4_4505.xml · nonDerivative · entry 2 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,231 F1 · kind: Consists of shares withheld by Albany Molecular Research, Inc. in order to satisfy the minimum tax withholding obligation of the reporting person. Read SEC document |
| January 31, 2017 Filed Feb 1, 2017 16:07 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Tax withholdingCommon Stock | 553 | $18.11 | $10,014.83 |
DisclosureSEC source: 0001638599-17-000135 · doc4_4505.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,784 F1 · kind: Consists of shares withheld by Albany Molecular Research, Inc. in order to satisfy the minimum tax withholding obligation of the reporting person. Read SEC document |
| November 16, 2016 Filed Nov 17, 2016 16:12 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | SaleCommon Stock | 6,000 | $17.00 | $102,000.00 |
DisclosureSEC source: 0001638599-16-001581 · doc4_4328.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,337 Read SEC document |
| November 02, 2016 Filed Nov 3, 2016 16:54 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Tax withholdingCommon Stock | 409 | $15.09 | $6,171.81 |
DisclosureSEC source: 0001638599-16-001481 · doc4_4269.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,337 F1 · kind: Consists of shares withheld by Albany Molecular Research, Inc. in order to satisfy the minimum tax withholding obligation of the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.